Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 16/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25172509 | 1.00 | KDM4E (0.45) | KDM4ECYP2C19NOTUMHSD17B10MEN1 | |
| SCHEMBL31217266 | 0.93 | KDM4E (0.51) | KDM4ECYP2C19HSD17B10MEN1ALDH1A1 | |
| SCHEMBL18450235 | 0.87 | KDM4E (0.44) | KDM4EMEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL25447223 | 0.87 | KDM4E (0.44) | KDM4EMEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL30313340 | 0.84 | USP30 (0.48) | KDM4ECYP2C19USP30 | |
| SCHEMBL18128248 | 0.83 | USP30 (0.37) | KDM4ECYP2C19USP30 | |
| SCHEMBL18128247 | 0.83 | USP30 (0.37) | KDM4ECYP2C19USP30 | |
| SCHEMBL18128251 | 0.83 | USP30 (0.37) | KDM4ECYP2C19USP30 | |
| SCHEMBL25416132 | 0.82 | FFAR4 (0.40) | USP30 | |
| SCHEMBL2183987 | 0.82 | USP30 (0.48) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | KDM4E 332/4885CYP2C19 2658/4885NOTUM 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.